Biodistribution and radiation dosimetry of stabilized 99mTc-exametazine-labeled leukocytes in normal subjects
Labeling leukocytes with 99mTc-exametazime is a validated technique for imaging infection and inflammation. A new radiolabeling technique has recently been described that enables leukocyte labeling with a more stable form of 99mTc-exametazime. A normal value study of stabilized 99mTc-exametazime-lab...
Gespeichert in:
Veröffentlicht in: | The Journal of nuclear medicine (1978) 2000-05, Vol.41 (5), p.934 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 5 |
container_start_page | 934 |
container_title | The Journal of nuclear medicine (1978) |
container_volume | 41 |
creator | Robins, P D Salazar, I Forstrom, L A Mullan, B P Hung, J C |
description | Labeling leukocytes with 99mTc-exametazime is a validated technique for imaging infection and inflammation. A new radiolabeling technique has recently been described that enables leukocyte labeling with a more stable form of 99mTc-exametazime. A normal value study of stabilized 99mTc-exametazime-labeled leukocytes has been performed, including biodistribution and dosimetry estimates in normal subjects.
Ten volunteers were injected with stabilized 99mTc-exametazime-labeled autologous leukocytes to study labeled leukocyte kinetics and dosimetry in normal subjects. Serial whole-body imaging and blood sampling were performed up to 24 h after injection. Cell-labeling efficiency and in vivo viability, organ dosimetry, and clearance calculations were obtained from the blood samples and imaging data as well as urine and stool collection up to 36 h after injection.
Cell-labeling efficiency of 87.5% +/- 5.1% was achieved, which is similar to or better than that reported with the standard preparation of 99mTc-exametazime. In vivo stability of the radiolabeled leukocytes was also similar to in vitro results with stabilized 99mTc-exametazime and better than previously reported in vivo stability for nonstabilized 99mTc-exametazime-labeled leukocytes. Organ dosimetry and radiation absorbed doses were similar with a whole-body absorbed dose of 1.3 x 10(-3) mGy/ MBq. Urinary and fecal excretion of activity was minimal, and visual assessment of the images showed little renal parenchymal activity and no bowel activity up to 2 h after injection.
Cell labeling and in vivo stability appear improved compared with the leukocytes labeled with the nonstabilized preparation of 99mTc-exametazime. There are advantages in more cost-effective preparation of the stabilized 99mTc-exametazime and an extended window for clinical usage, with good visualization of abdominal structures on early images. No significant increase in specific organ and whole-body dosimetry estimates was noted compared with previous estimates using nonstabilized 99mTc-exametazime-labeled leukocytes. |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_10809211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10809211</sourcerecordid><originalsourceid>FETCH-LOGICAL-p541-3e7ed6194944213aa9bb5a4bf1ac5af5a70f4ef015d8135e9c1b61d5dde3a5153</originalsourceid><addsrcrecordid>eNo1j8tqwzAQRbVoadK0v1D0AwZNJDnWsg19QaAb78PIGoFS2zKSDHW-vqGP1eFy4MK5YmsBNVRaC71itzmfhBB10zQ3bAWiEWYLsGbDU4gu5JKCnUuII8fR8YQu4M9yMYeBSlp49DwXtKEPZ3LcmKHtKvrCi8RzGKnq0VJ_MT3Nn7FbCmUeRj7GNGDP82xP1JV8x6499pnu_7hh7ctzu3-rDh-v7_vHQzVpBZWkHbkajDJKbUEiGms1KusBO41e4054RV6Adg1ITaYDW4PTzpFEDVpu2MPv7TTbgdxxSmHAtBz_s-U3wVdV7w</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Biodistribution and radiation dosimetry of stabilized 99mTc-exametazine-labeled leukocytes in normal subjects</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Robins, P D ; Salazar, I ; Forstrom, L A ; Mullan, B P ; Hung, J C</creator><creatorcontrib>Robins, P D ; Salazar, I ; Forstrom, L A ; Mullan, B P ; Hung, J C</creatorcontrib><description>Labeling leukocytes with 99mTc-exametazime is a validated technique for imaging infection and inflammation. A new radiolabeling technique has recently been described that enables leukocyte labeling with a more stable form of 99mTc-exametazime. A normal value study of stabilized 99mTc-exametazime-labeled leukocytes has been performed, including biodistribution and dosimetry estimates in normal subjects.
Ten volunteers were injected with stabilized 99mTc-exametazime-labeled autologous leukocytes to study labeled leukocyte kinetics and dosimetry in normal subjects. Serial whole-body imaging and blood sampling were performed up to 24 h after injection. Cell-labeling efficiency and in vivo viability, organ dosimetry, and clearance calculations were obtained from the blood samples and imaging data as well as urine and stool collection up to 36 h after injection.
Cell-labeling efficiency of 87.5% +/- 5.1% was achieved, which is similar to or better than that reported with the standard preparation of 99mTc-exametazime. In vivo stability of the radiolabeled leukocytes was also similar to in vitro results with stabilized 99mTc-exametazime and better than previously reported in vivo stability for nonstabilized 99mTc-exametazime-labeled leukocytes. Organ dosimetry and radiation absorbed doses were similar with a whole-body absorbed dose of 1.3 x 10(-3) mGy/ MBq. Urinary and fecal excretion of activity was minimal, and visual assessment of the images showed little renal parenchymal activity and no bowel activity up to 2 h after injection.
Cell labeling and in vivo stability appear improved compared with the leukocytes labeled with the nonstabilized preparation of 99mTc-exametazime. There are advantages in more cost-effective preparation of the stabilized 99mTc-exametazime and an extended window for clinical usage, with good visualization of abdominal structures on early images. No significant increase in specific organ and whole-body dosimetry estimates was noted compared with previous estimates using nonstabilized 99mTc-exametazime-labeled leukocytes.</description><identifier>ISSN: 0161-5505</identifier><identifier>PMID: 10809211</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Female ; Humans ; Leukocytes ; Male ; Radiation Dosage ; Radiopharmaceuticals - pharmacokinetics ; Reference Values ; Technetium Tc 99m Exametazime - pharmacokinetics ; Tissue Distribution</subject><ispartof>The Journal of nuclear medicine (1978), 2000-05, Vol.41 (5), p.934</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10809211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robins, P D</creatorcontrib><creatorcontrib>Salazar, I</creatorcontrib><creatorcontrib>Forstrom, L A</creatorcontrib><creatorcontrib>Mullan, B P</creatorcontrib><creatorcontrib>Hung, J C</creatorcontrib><title>Biodistribution and radiation dosimetry of stabilized 99mTc-exametazine-labeled leukocytes in normal subjects</title><title>The Journal of nuclear medicine (1978)</title><addtitle>J Nucl Med</addtitle><description>Labeling leukocytes with 99mTc-exametazime is a validated technique for imaging infection and inflammation. A new radiolabeling technique has recently been described that enables leukocyte labeling with a more stable form of 99mTc-exametazime. A normal value study of stabilized 99mTc-exametazime-labeled leukocytes has been performed, including biodistribution and dosimetry estimates in normal subjects.
Ten volunteers were injected with stabilized 99mTc-exametazime-labeled autologous leukocytes to study labeled leukocyte kinetics and dosimetry in normal subjects. Serial whole-body imaging and blood sampling were performed up to 24 h after injection. Cell-labeling efficiency and in vivo viability, organ dosimetry, and clearance calculations were obtained from the blood samples and imaging data as well as urine and stool collection up to 36 h after injection.
Cell-labeling efficiency of 87.5% +/- 5.1% was achieved, which is similar to or better than that reported with the standard preparation of 99mTc-exametazime. In vivo stability of the radiolabeled leukocytes was also similar to in vitro results with stabilized 99mTc-exametazime and better than previously reported in vivo stability for nonstabilized 99mTc-exametazime-labeled leukocytes. Organ dosimetry and radiation absorbed doses were similar with a whole-body absorbed dose of 1.3 x 10(-3) mGy/ MBq. Urinary and fecal excretion of activity was minimal, and visual assessment of the images showed little renal parenchymal activity and no bowel activity up to 2 h after injection.
Cell labeling and in vivo stability appear improved compared with the leukocytes labeled with the nonstabilized preparation of 99mTc-exametazime. There are advantages in more cost-effective preparation of the stabilized 99mTc-exametazime and an extended window for clinical usage, with good visualization of abdominal structures on early images. No significant increase in specific organ and whole-body dosimetry estimates was noted compared with previous estimates using nonstabilized 99mTc-exametazime-labeled leukocytes.</description><subject>Adult</subject><subject>Female</subject><subject>Humans</subject><subject>Leukocytes</subject><subject>Male</subject><subject>Radiation Dosage</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Reference Values</subject><subject>Technetium Tc 99m Exametazime - pharmacokinetics</subject><subject>Tissue Distribution</subject><issn>0161-5505</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j8tqwzAQRbVoadK0v1D0AwZNJDnWsg19QaAb78PIGoFS2zKSDHW-vqGP1eFy4MK5YmsBNVRaC71itzmfhBB10zQ3bAWiEWYLsGbDU4gu5JKCnUuII8fR8YQu4M9yMYeBSlp49DwXtKEPZ3LcmKHtKvrCi8RzGKnq0VJ_MT3Nn7FbCmUeRj7GNGDP82xP1JV8x6499pnu_7hh7ctzu3-rDh-v7_vHQzVpBZWkHbkajDJKbUEiGms1KusBO41e4054RV6Adg1ITaYDW4PTzpFEDVpu2MPv7TTbgdxxSmHAtBz_s-U3wVdV7w</recordid><startdate>200005</startdate><enddate>200005</enddate><creator>Robins, P D</creator><creator>Salazar, I</creator><creator>Forstrom, L A</creator><creator>Mullan, B P</creator><creator>Hung, J C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200005</creationdate><title>Biodistribution and radiation dosimetry of stabilized 99mTc-exametazine-labeled leukocytes in normal subjects</title><author>Robins, P D ; Salazar, I ; Forstrom, L A ; Mullan, B P ; Hung, J C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p541-3e7ed6194944213aa9bb5a4bf1ac5af5a70f4ef015d8135e9c1b61d5dde3a5153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Female</topic><topic>Humans</topic><topic>Leukocytes</topic><topic>Male</topic><topic>Radiation Dosage</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Reference Values</topic><topic>Technetium Tc 99m Exametazime - pharmacokinetics</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robins, P D</creatorcontrib><creatorcontrib>Salazar, I</creatorcontrib><creatorcontrib>Forstrom, L A</creatorcontrib><creatorcontrib>Mullan, B P</creatorcontrib><creatorcontrib>Hung, J C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robins, P D</au><au>Salazar, I</au><au>Forstrom, L A</au><au>Mullan, B P</au><au>Hung, J C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biodistribution and radiation dosimetry of stabilized 99mTc-exametazine-labeled leukocytes in normal subjects</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><addtitle>J Nucl Med</addtitle><date>2000-05</date><risdate>2000</risdate><volume>41</volume><issue>5</issue><spage>934</spage><pages>934-</pages><issn>0161-5505</issn><abstract>Labeling leukocytes with 99mTc-exametazime is a validated technique for imaging infection and inflammation. A new radiolabeling technique has recently been described that enables leukocyte labeling with a more stable form of 99mTc-exametazime. A normal value study of stabilized 99mTc-exametazime-labeled leukocytes has been performed, including biodistribution and dosimetry estimates in normal subjects.
Ten volunteers were injected with stabilized 99mTc-exametazime-labeled autologous leukocytes to study labeled leukocyte kinetics and dosimetry in normal subjects. Serial whole-body imaging and blood sampling were performed up to 24 h after injection. Cell-labeling efficiency and in vivo viability, organ dosimetry, and clearance calculations were obtained from the blood samples and imaging data as well as urine and stool collection up to 36 h after injection.
Cell-labeling efficiency of 87.5% +/- 5.1% was achieved, which is similar to or better than that reported with the standard preparation of 99mTc-exametazime. In vivo stability of the radiolabeled leukocytes was also similar to in vitro results with stabilized 99mTc-exametazime and better than previously reported in vivo stability for nonstabilized 99mTc-exametazime-labeled leukocytes. Organ dosimetry and radiation absorbed doses were similar with a whole-body absorbed dose of 1.3 x 10(-3) mGy/ MBq. Urinary and fecal excretion of activity was minimal, and visual assessment of the images showed little renal parenchymal activity and no bowel activity up to 2 h after injection.
Cell labeling and in vivo stability appear improved compared with the leukocytes labeled with the nonstabilized preparation of 99mTc-exametazime. There are advantages in more cost-effective preparation of the stabilized 99mTc-exametazime and an extended window for clinical usage, with good visualization of abdominal structures on early images. No significant increase in specific organ and whole-body dosimetry estimates was noted compared with previous estimates using nonstabilized 99mTc-exametazime-labeled leukocytes.</abstract><cop>United States</cop><pmid>10809211</pmid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0161-5505 |
ispartof | The Journal of nuclear medicine (1978), 2000-05, Vol.41 (5), p.934 |
issn | 0161-5505 |
language | eng |
recordid | cdi_pubmed_primary_10809211 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adult Female Humans Leukocytes Male Radiation Dosage Radiopharmaceuticals - pharmacokinetics Reference Values Technetium Tc 99m Exametazime - pharmacokinetics Tissue Distribution |
title | Biodistribution and radiation dosimetry of stabilized 99mTc-exametazine-labeled leukocytes in normal subjects |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T08%3A35%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biodistribution%20and%20radiation%20dosimetry%20of%20stabilized%2099mTc-exametazine-labeled%20leukocytes%20in%20normal%20subjects&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Robins,%20P%20D&rft.date=2000-05&rft.volume=41&rft.issue=5&rft.spage=934&rft.pages=934-&rft.issn=0161-5505&rft_id=info:doi/&rft_dat=%3Cpubmed%3E10809211%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10809211&rfr_iscdi=true |